Avtor/Urednik		Rajčević, Uroš
Naslov		Adoptivna celična terapija in limfociti T z izraženimi himernimi antigenskimi receptorji
Prevedeni naslov		Adoptive Cell Therapy and chimeric antigen receptor - T cells
Tip		članek
Vol. in št.		Letnik 89, št. 7/8
Leto izdaje		2020
Obseg		str. 398-407
ISSN		1318-0347 - Zdravniški vestnik : glasilo Slovenskega zdravniškega društva : Slovenian medical journal
Jezik		slv
Abstrakt		In cancer therapy, currently used approaches include surgery, radio- and chemotherapy and various combinations of these. Immunotherapy is emerging as the "fourth pillar" of cancer therapy. Science Magazine declared cancer immunotherapy as a "breakthrough of the year" in 2013. While antibody therapies and cytokines have been in use for a longer period of time, the cell immunotherapies are only gaining momentum in recent years, especially thanks to adoptive T-cell therapy (ATC). Adoptive T-cell therapy, which is subject of this article can be divided mostly to therapies with tumor-infiltrating lymphocytes (TIL) and to therapies using T-cells genetically modified with transgenic T-cell receptors (TCR) or chimeric antigen receptors (CAR). All of these therapies are exclusively personalized and are at the moment based on the autologous transplant of the patient's own cells. Therapeutic cells are prepared for each patient individually, which carries a great impact on the processes of their development and production, as well as the logistics and costsinvolved. The new mode of therapies with CAR-T, for specific diseases at the moment the only registered mode of ATC, causes revolutionary breakthroughs in the development of such advanced therapeutics and, consequently in clinical oncology. CAR-T therapy is achieving an incredible success in clinical practice especially in combat against hematological cancers, while the treatment of patients with solid tumours it has not been as successful. Along with that, due to great complexity of the CAR-T therapy, it is accompanied by frequent and severe side effects which can be fatal in worst cases. By adopting adequate measures, these effects can be controlled and partially mitigated. CAR-T therapy is being introduced to Slovenia through registered, commercially accessible therapeutics of this kind, while the access to other ATC is still pending. At the same time, in Slovenia in this field, we are developing our own knowledge and technology, hoping that new, efficient treatment modalities become accessible to a wider population of patients as soon as possible.
Proste vsebinske oznake		adoptivna celična terapija imunoterapija CAR-T adoptive cell therapy immunotherapy CAR-T